Cajot J F, Sordat B, Kruithof E K, Bachmann F
J Natl Cancer Inst. 1986 Sep;77(3):703-12. doi: 10.1093/jnci/77.3.703.
Analysis was made of plasminogen activator (PA) activities present in 0.125% Triton X-100 extracts of human primary colon carcinomas and of their respective serial subcutaneous xenografts in nude mice. A correlation between tumor invasiveness and PA expression was observed in that primary tumors exhibiting clearly invasive growth patterns demonstrated high concentrations of PAs while subcutaneous xenografts, exhibiting noninvasive pseudobenign growth, contained very low levels of PA activity. The decrease in fibrinolytic activity observed in subcutaneous xenografts was not due to an increase in inhibitors of fibrinolytic activity. Immunologic characterization of PAs in tumor extracts showed that over 90% of human PA activity was of the urokinase type. Furthermore, tumor-derived urokinase was shown to be present in a proenzyme form. It was resistant to diisopropyl fluorophosphate (DFP) and was not inhibited by purified PA inhibitor. However, after its activation into urokinase by plasmin, it was completely inhibited by DFP and PA inhibitor.
对人原发性结肠癌及其在裸鼠中的相应系列皮下异种移植物的0.125% Triton X - 100提取物中的纤溶酶原激活剂(PA)活性进行了分析。观察到肿瘤侵袭性与PA表达之间存在相关性,即呈现明显侵袭性生长模式的原发性肿瘤显示出高浓度的PA,而呈现非侵袭性假良性生长的皮下异种移植物含有非常低水平的PA活性。在皮下异种移植物中观察到的纤溶活性降低并非由于纤溶活性抑制剂的增加。肿瘤提取物中PA的免疫特性表明,超过90%的人PA活性属于尿激酶型。此外,肿瘤来源的尿激酶以酶原形式存在。它对二异丙基氟磷酸酯(DFP)有抗性,且不受纯化的PA抑制剂抑制。然而,在被纤溶酶激活为尿激酶后,它被DFP和PA抑制剂完全抑制。